ASTELLAS PHARMA UNSP.ADR (YPHA) - Total Liabilities
Based on the latest financial reports, ASTELLAS PHARMA UNSP.ADR (YPHA) has total liabilities worth €1.83 Trillion EUR (≈ $2.14 Trillion USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ASTELLAS PHARMA UNSP.ADR equity growth rate to track the company's year-over-year net asset growth rate.
ASTELLAS PHARMA UNSP.ADR - Total Liabilities Trend (2022–2025)
This chart illustrates how ASTELLAS PHARMA UNSP.ADR's total liabilities have evolved over time, based on quarterly financial data. See YPHA FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
ASTELLAS PHARMA UNSP.ADR Competitors by Total Liabilities
The table below lists competitors of ASTELLAS PHARMA UNSP.ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Amcor PLC
NYSE:AMCR
|
USA | $25.40 Billion |
|
Helvetia Holding AG
SW:HELN
|
Switzerland | CHF55.78 Billion |
|
AXIA Energia
NYSE:AXIA
|
USA | $157.16 Billion |
|
Fubon Financial Holding Co Ltd Pref B
TW:2881B
|
Taiwan | NT$11.88 Trillion |
|
Centrais Elétricas Brasileiras S.A. - Eletrobrás
F:L3XB
|
Germany | €161.18 Billion |
|
Moderna Inc
NASDAQ:MRNA
|
USA | $4.08 Billion |
|
AerCap Holdings N.V
F:R1D
|
Germany | €53.02 Billion |
|
Centrais Elétricas Brasileiras S.A. - Eletrobrás
SA:AXIA3
|
Brazil | R$156.60 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down ASTELLAS PHARMA UNSP.ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of ASTELLAS PHARMA UNSP.ADR.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ASTELLAS PHARMA UNSP.ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ASTELLAS PHARMA UNSP.ADR (2022–2025)
The table below shows the annual total liabilities of ASTELLAS PHARMA UNSP.ADR from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €1.83 Trillion ≈ $2.14 Trillion |
-7.46% |
| 2024-03-31 | €1.97 Trillion ≈ $2.31 Trillion |
+108.06% |
| 2023-03-31 | €948.56 Billion ≈ $1.11 Trillion |
+8.77% |
| 2022-03-31 | €872.09 Billion ≈ $1.02 Trillion |
-- |
About ASTELLAS PHARMA UNSP.ADR
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms… Read more